Literature DB >> 25222500

Bone marrow graft as a source of allogeneic hematopoietic stem cells in patients undergoing a reduced intensity conditioning regimen.

E Gomez1, R Duléry1, C Langlois2, V Coiteux1, L Terriou1, L Magro1, J Gauthier1, E de Berranger1, A Duhamel2, I Yakoub-Agha1.   

Abstract

In an attempt to reduce the incidence of chronic GVHD (cGVHD) after reduced-intensity conditioning (RIC), we used BM instead of PBSC and added melphalan 100 mg/m(2) to the classical association of fludarabine, 30 mg/m(2)/day for 3 days and TBI, 200 cGy (FLUIM regimen). Between 2000 and 2012, 51 patients received BM with the FLUIM regimen (group A), and 124 received BM (n=22) or PBSC (n=102) with another RIC regimen (group B). Donors were siblings (n=123) or HLA-matched 10/10 unrelated (n=52). Full donor-type chimerism at day 100 was more often recorded in group A (86%) than in group B (62%); P<0.001. There was no difference between the two groups in terms of OS and EFS, acute GVHD, relapse and non-relapse mortality incidence. cGVHD occurred more often in group B (41%) than in group A (23%); P=0.021. In multivariate analysis, the two risk factors associated with the development of cGVHD were conditioning in group B (hazard ratio (HR)=2.871, 95% confidence interval (CI) (1.372-6.006); P=0.005) and CD34(+) count (HR=1.009, 95% CI (1.006-1.011); P<0.001). In conclusion, the FLUIM regimen followed by BM leads to more frequent full-donor chimerism and a reduced incidence of cGVHD without compromising relapse and survival.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25222500     DOI: 10.1038/bmt.2014.193

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  45 in total

1.  Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation.

Authors:  Andrea Bacigalupo; Teresa Lamparelli; Giovanni Barisione; Paolo Bruzzi; Stefano Guidi; Paolo Emilio Alessandrino; Paolo di Bartolomeo; Rosi Oneto; Barbara Bruno; Nicoletta Sacchi; Maria Teresa van Lint; Alberto Bosi
Journal:  Biol Blood Marrow Transplant       Date:  2006-05       Impact factor: 5.742

2.  [How to handle unexpected biological abnormalities observed in the pre-donation workup for hematopoietic stem cell transplantation: an SFGM-TC report on pre-transplant cytomegalovirus, Epstein-Barr virus, Toxoplasma gondii, or syphilis IgM positive serology test].

Authors:  R Duléry; C Giraud; J-L Beaumont; K Bilger; C Borel; N Dhedin; A Thiebaut; E Willems; S Alain; S Alfandari; A Dewilde; J-P Jouet; N Milpied; I Yakoub-Agha
Journal:  Pathol Biol (Paris)       Date:  2013-09-04

3.  A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies.

Authors:  A C Vigorito; W M Azevedo; J F Marques; A M Azevedo; K A Eid; F J Aranha; I Lorand-Metze; G B Oliveira; M E Correa; A R Reis; E C Miranda; C A de Souza
Journal:  Bone Marrow Transplant       Date:  1998-12       Impact factor: 5.483

Review 4.  The systemic administration of intravenous melphalan.

Authors:  G Sarosy; B Leyland-Jones; P Soochan; B D Cheson
Journal:  J Clin Oncol       Date:  1988-11       Impact factor: 44.544

5.  Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation.

Authors:  D Weisdorf; R Hakke; B Blazar; W Miller; P McGlave; N Ramsay; J Kersey; A Filipovich
Journal:  Transplantation       Date:  1991-06       Impact factor: 4.939

6.  Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma.

Authors:  Takeshi Saito; Yoshinobu Kanda; Masahiro Kami; Kazunori Kato; Nahoko Shoji; Sachiyo Kanai; Toshihiro Ohnishi; Yoshifumi Kawano; Kunihisa Nakai; Toshie Ogasawara; Hiroshi Matsubara; Atsushi Makimoto; Ryuji Tanosaki; Kensei Tobinai; Hiro Wakasugi; Yoichi Takaue; Shin Mineishi
Journal:  Clin Cancer Res       Date:  2002-04       Impact factor: 12.531

Review 7.  Mixed chimerism: preclinical studies and clinical applications.

Authors:  P A McSweeney; R Storb
Journal:  Biol Blood Marrow Transplant       Date:  1999       Impact factor: 5.742

Review 8.  CD34 + cell dose and outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation.

Authors:  M Díez-Campelo; J A Pérez-Simón; E M Ocio; C Castilla; J R González-Porras; F M Sánchez-Guijo; L Vázquez; M D Caballero; M C Cañizo; J F San Miguel
Journal:  Leuk Lymphoma       Date:  2005-02

9.  Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma.

Authors:  Gösta Gahrton; Simona Iacobelli; Giuseppe Bandini; Bo Björkstrand; Paolo Corradini; Charles Crawley; Ute Hegenbart; Gareth Morgan; Nicolaus Kröger; Anton Schattenberg; Stefan O Schönland; Leo F Verdonck; Lisa Volin; Theo de Witte; Dietger Niederwieser
Journal:  Haematologica       Date:  2007-11       Impact factor: 9.941

10.  High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation.

Authors:  Stephanie J Lee; John Klein; Michael Haagenson; Lee Ann Baxter-Lowe; Dennis L Confer; Mary Eapen; Marcelo Fernandez-Vina; Neal Flomenberg; Mary Horowitz; Carolyn K Hurley; Harriet Noreen; Machteld Oudshoorn; Effie Petersdorf; Michelle Setterholm; Stephen Spellman; Daniel Weisdorf; Thomas M Williams; Claudio Anasetti
Journal:  Blood       Date:  2007-09-04       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.